Targeting ceramide metabolism - A strategy for overcoming drug resistance

Journal of the National Cancer Institute

Volumn 93, Issue 5, 2001, Pages 347-357

  Senchenkov, Alex ^a   Litvak, David A ^a   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; CERAMIDE; CISPLATIN; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DIPHTHERIA TOXIN; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; FLUDARABINE; FUMONISIN B1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MIFEPRISTONE; NUCLEOSIDE ANALOG; PACLITAXEL; RETINOID; SURAMIN; TAMOXIFEN; TOREMIFENE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

CANCER CELL; CANCER THERAPY; CELL DEATH; CHEMOTHERAPY; CONTROLLED STUDY; DEGENERATION; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; IONIZING RADIATION; LIPID METABOLISM; LIPOGENESIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION;

EID: 0035819885     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.5.347     Document Type: Review

References (150)

1. Expression of resistance factors (P-glycoprotein, glutathione S- transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas
2. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture
3. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine
4. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
5. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein
6. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
7. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs
8. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines
9. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
10. Glutathione S-transferases and drug resistance
11. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
12. The dual role of mutant p53 protein in chemosensitivity in human cancers
13. Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin
14. Vaults are up-regulated in multidrug-resistant cancer cell lines
15. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells
16. Accumulation of glucosylceramides in multidrug-resistant cancer cells
17. Glucosylceramide: A marker for multiple-drug resistant cancers
18. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity
19. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells
20. Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis
21. 1,2-Diacylglycerols but not phorbol esters stimulate sphingomyelin hydrolysis in GH3 pituitary cells
22. 1,2-Diacylglycerols, but not phorbol esters, activate a potential inhibitory pathway for protein kinase C in GH3 pituitary cells. Evidence for involvement of a sphingomyelinase
23. Sphingomyelinase action inhibits phorbol ester-induced differentiation of human promyelocytic leukemic (HL-60) cells
24. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
25. Ceramide prevents neuronal programmed cell death induced by nerve growth factor deprivation
26. Sphingomyelin breakdown and cell fate
27. Sphingolipid metabolism and cell growth regulation
28. Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B
29. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation
30. Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor alpha
31. Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide
32. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis
33. Radiation-induced signal transduction and stress response
34. Ceramide formation during heat shock: A potential mediator of alpha B-crystallin transcription
35. 1-beta-D-Arabinofuranosyl-cytosine stimulates ceramide and diglyceride formation in HL-60 cells
36. The role of ceramide in the cellular response to cytotoxic agents
37. Lipid signaling in CD95-mediated apoptosis
38. Stress signals for apoptosis: Ceramide and c-Jun kinase
39. Functions of ceramide in coordinating cellular responses to stress
40. Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases
41. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation
42. Regulation of ceramide production and apoptosis
43. The sphingomyelin cycle and the second messenger function of ceramide
44. Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3- induced HL-60 cell differentiation
45. Ceramide signaling in apoptosis
46. Diversity and complexity of ceramide signalling in apoptosis
47. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
48. Renaturation and tumor necrosis factor-alpha stimulation of a 97-kDa ceramide-activated protein kinase
49. Sterospecific induction of apoptosis in U937 cells by N-octanoyl-sphingosine steroisomers and N-octyl-sphingosine. The ceramide amide group is not required for apoptosis
50. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction
51. Ceramide activates heterotrimeric protein phosphatase 2A
52. Phosphorylation of Raf by ceramide-activated protein kinase
53. Interleukin-1 activates p54 mitogen-activated protein (MAP) kinase/stress-activated protein kinase by a pathway that is independent of p21ras, Raf-1, and MAP kinase kinase
54. Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades
55. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells
56. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
57. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling
58. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase
59. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis
60. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling
61. All along the watchtower: On the regulation of apoptosis regulators
62. Cytokine response modifier A (Crm A) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway
63. Bcl-2 interrupts the ceramide-mediated pathway of cell death
64. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase
65. Ceramide induces apoptosis via CPP32 activation
66. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme
67. Daunorubicin-induced apoptosis: Triggering of ceramide generation through sphingomyelin hydrolysis
68. Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells
69. Apoptosis-a cell mechanism important for cytotoxic response to adriamycin and a lipid metabolic pathway that facilitates escape
70. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics
71. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells
72. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells
73. Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide
74. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells
75. Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line
76. Taxol-induced ceramide generation and apoptosis in human breast cancer cells
77. Tamoxifen retards glycosphingolipid metabolism in human cancer cells
78. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells
79. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells
80. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells
81. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4- hydroxyphenyl)-retinamide in neuroblastoma cell lines
82. Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR)
83. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice
84. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
85. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF
86. 388-GM-CSF, a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor
87. Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines
88. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells
89. Role of ceramide in suramin-induced cancer cell death
90. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice
91. Evaluation of continuous infusion suramin in metastatic breast cancer: Impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins
92. Chemotherapy in advanced prostate cancer
93. Chemotherapy for hormone refractory prostate cancer
94. Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis
95. Serine palmitoyltransferase regulated de novo ceramide generation during etoposide-induced apoptosis
96. 2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase 3-like activity in Molt-4 cells in response to synthase inhibition by GW1843
97. The vitamin D3 analogue, calcipotriol, induces sphingomyelin hydrolysis in human keratinocytes
98. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
99. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism
100. Sequential operation of ceramide synthesis and ICE cascade in CPT-11-initiated apoptotic death signaling
101. Ceramide generation in nitric oxide-induced apoptosis. Activation of magnesium-dependent neutral sphingomyelinase via caspase-3
102. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis
103. Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling
104. Loss of ceramide production confers resistance to radiation-induced apoptosis
105. Radio-sensitive murine thymoma cell line 3SB: Characterization of its apoptosis-resistant variants induced by repeated X-irradiation
106. Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis
107. Ceramide and apoptosis
108. Ceramide in apoptosis-does it really matter?
109. Apoptosis in cancer therapy: Crossing the threshold
110. Apoptosis and cancer
111. Tumor cell apoptosis present at diagnosis may predict treatment outcome for patients with medulloblastoma
112. Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic Kym-1 cells
113. Human acid ceramidase is overexpressed but not mutated in prostate cancer
114. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death
115. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin
116. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
117. Future perspectives for the development of P-glycoprotein modulators
118. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro
119. PhaseI/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
120. Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase
121. Antitumor activity via inhibition of glycosphingolipid biosynthesis
122. Glucosphingolipids as sites of action in the chemotherapy of cancer
123. Chemotherapy by slowing glucosphingolipid synthesis
124. Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells
125. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma
126. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma
127. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen
128. Altering glycolipid metabolism in MDR cells, new ideas in cancer treatment
129. The impact of toremifene, a novel antiestrogen and adriamycin on ceramide metabolism and modulation of multidrug resistance (MDR)
130. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine
131. Growth inhibitory and apoptotic effects of RU486 on MCF-7 and T-47D breast cancer cells
132. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells
133. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells
134. Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-Va12]- Cyclosporine), a multidrug resistance modulator, with P-glycoprotein
135. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation
136. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein
137. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein
138. Improved inhibitors of glucosylceramide synthase
139. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase
140. Apoptosis induced by N-hexanoylsphingosine in CHP-100 cells associates with accumulation of endogenous ceramide and is potentiated by inhibition of glucocerebroside synthesis
141. N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis
142. N-Butyldeoxygalactonojirimycin: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo
143. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)-retinamide and modulators of ceramide metabolism
144. 1-Pheny1-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine
145. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance
146. Ceramide glycosylation potentiates cellular multidrug resistance
147. Ceramide accumulation precedes caspase-dependent apoptosis in CHP-100 neuroepithelioma cells exposed to the protein phosphatase inhibitor okadaic acid
148. Ceramide generation in response to photodynamic treatment of L5178Y mouse lymphoma cells